NCT01953003View on ClinicalTrials.gov

Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

112

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions

Malignant Neoplasm of Breast

Interventions

DRUG

vinflunine

intravenous administration day 1 once every 3 weeks, 280 mg/m²

DRUG

Capecitabine

Arm A : 1650 mg/m² Arm B : 2500 mg/m²

Trial Locations (18)

119228

NUH, Singapore

258500

Gleneagles Hospital, Singapore

Unknown

Beijing

Changchun

Chengdu

Dalian

Fuzhou

Hangzhou

Harbin

Jinan

Nanjing

Shanghai

Shenyang

Tianjin

Wuhan

Kaohsiung City

Taichung

Taipei

All Listed Sponsors

lead

Pierre Fabre Medicament

INDUSTRY

NCT01953003 - Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | Biotech Hunter | Biotech Hunter